May 02, 2023
Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma
Apr 30, 2023
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
Apr 26, 2023
Immutep Quarterly Activities Report
Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting
Immutep Appoints Dr. Florian Vogl as Chief Medical Officer
